http://www.biospace.comBioSpace RSS GeneratorSun, 26 May 2013 02:18:57 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.foxbusiness.com/news/2013/04/15/roche-ascletis-to-collaborate-on-hepatitis-c-drugs-for-china/Roche Holding AG (ROG.VX) Mondat said it and Ascletis have entered into a collaboration to develop and commercialize Roche's investigational drug danoprevir in China for the treatment of Hepatitis-C Virus (HCV). - It is estimated that more than 10 million patients in China are chronically infected with HCV. - The majority of these are genotype 1b, which has proven highly responsive to danoprevir. ...Mon, 15 Apr 2013 12:00:00 AM GMThttp://www.reuters.com/article/2013/04/10/glaxosmithkline-electroceuticals-idUSL5N0CW0NB20130410Drug discovery typically was initially a chemistry endeavor. Biological drugs, made from biological processes, was the next breakthrough. GlaxoSmithKline (NYSE: GSK) wants to see new treatments can be found in yet another way by targeting electrical signals in the body. To encourage the effort, the company said on Wednesday it is offering a $1 million prize and funding up to 40 researchers working...Thu, 11 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292747&full=11. Singapore, 9 April 2013 GlaxoSmithKline (GSK) and A*STARs Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit.</p><p>2. ICES has a long standing relationship with GSK since 2003, and...Tue, 09 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292633&full=1 <div class"xn-content"><p><b>Transaction Designed to Enhance Shareholder Value By Unlocking Value of the Epigenetics Platform</b></p><p>TSX Exchange Symbol: <b>RVX</b></p><p align"justify"><span class"xn-location">CALGARY</span>, <span class"xn-chron">April 8, 2013</span> /PRNewswire/ - Resverlogix Corp. (TSX:RVX) ("Resverlogix") today announced that its Board of Directors has approved...Mon, 08 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292623&full=1BASEL, Switzerland</span>, and <span class"xn-location">CARLSBAD, Calif.</span></span>, <span><span class"xn-chron">April 8, 2013</span></span> /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Isis Pharmaceuticals, Inc (NASDAQ: ISIS) today announced that they have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology...Mon, 08 Apr 2013 12:00:00 AM GMThttp://www.xconomy.com/boston/2013/03/21/astrazeneca-shells-out-240m-upfront-for-moderna-mrna-drugs/The new CEO of AstraZeneca, Pascal Soriot, has just written a huge check, worth $240 million in upfront cash. Its going to a little biotech startup in Cambridge, MA, that started a couple years ago with a far-out idea for making drugs in a fast, cheap, and completely unorthodox way. London-based AstraZeneca (NYSE: AZN) is announcing today it has struck an exclusive partnership with Moderna Therapeutics...Fri, 22 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291177&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, a privately-held biotechnology company focused on gene therapy, today announced the formation of a broad, global strategic collaboration with Celgene Corporation to discover, develop and commercialize novel disease-altering gene therapies in oncology. The collaboration will focus on applying gene therapy technology to genetically modify a patients...Thu, 21 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290438&full=1 <div class"xn-content"><p><span class"xn-location">SAN DIEGO</span>, <span class"xn-chron">March 13, 2013</span> /PRNewswire/ -- Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13) antibody asset from AbbVie (NYSE: ABBV). </p><p>The asset, designated RPC4046 by Receptos, has completed a first-in-human...Thu, 14 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290150&full=1TOKYO</span> and <span class"xn-location">SAN DIEGO</span>, <span class"xn-chron">March 12, 2013</span> /PRNewswire/ -- Astellas Pharma Inc. (Astellas) (<span class"xn-location">Tokyo</span>: 4503) and Ambit Biosciences Corporation today announced the companies will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including...Wed, 13 Mar 2013 12:00:00 AM GMThttp://www.xconomy.com/seattle/2013/03/05/presage-snags-13m-from-celgene-to-pick-cancer-drug-winners/Seattle-based Presage Biosciences has found another big partner that thinks it can help separate the winners from the losers in early cancer drug development, before the really big bucks get wasted on bad experiments. Presage, a spinoff from the Fred Hutchinson Cancer Research Center, is announcing today it has struck a new partnership with Summit, NJ-based Celgene (NASDAQ: CELG), the worlds No. ...Tue, 05 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287919&full=1BASEL, Switzerland</span>, <span class"xn-location">NEW YORK</span> and <span class"xn-location">JERUSALEM</span></span>, <span class"xn-chron">Feb. 18, 2013</span> /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-az-ma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary...Wed, 20 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=288115&full=1WHITEHOUSE STATION, N.J. & SEOUL, South Korea Merck, (NYSE: MRK) known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates.</p><p>The combination of Mercks global commercial presence with Samsung Bioepis biologic development and manufacturing capabilities...Wed, 20 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287391&full=1LA JOLLA, Calif.</span>, <span class"xn-chron">Feb. 12, 2013</span> /PRNewswire/ -- RQx Pharmaceuticals, Inc. today announced that it has entered into a drug discovery collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the discovery and development of novel drug compounds for an undisclosed target. Under the terms of the agreement, RQx will receive an up-front...Tue, 12 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=286837&full=1DUBLIN--(BUSINESS WIRE)-- Elan Corporation, plc (ELN) today announced that it has agreed to restructure the Tysabri collaboration with Biogen Idec. Under the terms of the agreement, Elan will move from the current 50:50 business collaboration to an upfront payment of $3.25 billion and a double digit tiered royalty structure for the complete asset.</p><p>Highlights of Transaction Upon Closing...Thu, 07 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=286519&full=1PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The Medicines Company (MDCO) and Alnylam Pharmaceuticals, Inc. (ALNY), a leading RNAi therapeutics company, announced today that they have formed an exclusive global alliance for the development and commercialization of Alnylams ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia.</p><p>This new alliance unites two...Tue, 05 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=285437&full=1IRVINE, Calif. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Allergan, Inc. (AGN) and MAP Pharmaceuticals, Inc. (MAPP) today jointly announced that they have entered into a definitive merger agreement whereby Allergan will acquire 100% of the shares of MAP Pharmaceuticals for a price of $25.00 per share. MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies...Wed, 23 Jan 2013 12:00:00 AM GMThttp://www.streetinsider.com/Analyst+Comments/Jefferies+Says+Rumored+Life+Tech+(LIFE)+LBO+Should+Price+at+$50+to+$60Share/8017676.htmlLife Technologies Corp. (LIFE), a maker of DNA-sequencing equipment and laboratory materials, rose to its highest-ever value after the hiring of strategic advisers sparked speculation the company may be sold. Life Technologies jumped 9.3 percent to $60.10 at 9:43 a.m. New York time, after earlier touching to $61.28, its highest intraday price since the shares began trading in February 1999. The Carlsbad...Mon, 21 Jan 2013 12:00:00 AM GMThttp://uk.reuters.com/article/2013/01/16/us-markets-europe-stocks-idUKBRE90F0V320130116Shares in Shire (SHP.L) gained 2.3 percent in brisk volume on Wednesday, bucking a weaker European stock market, with traders citing rehashed talk of a potential bid from UK-listed pharmaceutical peer AstraZeneca (AZN.L). Shire's stock had traded 70 percent of its full-day volume average at 1341 GMT and it was among the top risers on the pan-European FTSEurofirst 300 index .FTEU3, down 0.3 percent...Thu, 17 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=284103&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that it has entered into a global collaboration agreement with Amgen Inc. to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors. The collaboration...Tue, 08 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=283850&full=1ROCKVILLE, Md.</span></span>, <span class"xn-chron">Jan. 7, 2013</span> /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced it has entered into a license agreement with Gilead Sciences, Inc. (Nasdaq: GILD) for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at up to four...Tue, 08 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=282049&full=1FOSTER CITY, Calif. & MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) announced today that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. The transaction has received the unanimous approval of YMs Board of Directors, and values YM at approximately U.S.$510 million...Thu, 13 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=281726&full=1THOUSAND OAKS, Calif.</span> and <span class"xn-location">REYKJAVIK, Iceland</span>, <span class"xn-chron">Dec. 10, 2012</span> /PRNewswire/ -- Amgen (NASDAQ:AMGN) and deCODE Genetics today announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics, a global leader in human genetics, headquartered in <span class"xn-location">Reykjavik, Iceland...Tue, 11 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=281882&full=1JERUSALEM & BURNABY, British Columbia--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd (TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that they have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is currently in clinical development for a variety of painful disorders. This product specifically targets sodium channels which are abundantly...Tue, 11 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=281691&full=1WESTON, Mass.</span> and <span class"xn-location">CARLSBAD, Calif.</span>, <span class"xn-chron">Dec. 10, 2012</span> /PRNewswire/ -- Biogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological...Mon, 10 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=280705&full=1WATERTOWN, Mass.--(BUSINESS WIRE)-- Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has entered into a strategic global collaboration with Sanofi (EURONEXT: SAN and NYSE: SNY) to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. Under the agreement...Thu, 29 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=279890&full=1RARITAN, NJ, November 15, 2012 -- Janssen Research & Development, LLC (Janssen R&D) today announced the establishment of a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Company are the first two companies to join Janssen in this effort. </p><p>The new Investigator Databank, established as part of...Thu, 15 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=279711&full=1NEW YORK & EMERYVILLE, Calif.--(BUSINESS WIRE)-- Forest Laboratories, Inc. (FRX), an international pharmaceutical company, and Adamas Pharmaceuticals, Inc. announced today that they have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR (memantine HCl extended release) and donepezil HCl as a once daily therapy for the treatment of...Wed, 14 Nov 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20121112005485&newsLang=enCAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. announced today a multi-year collaboration with AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a persons response or resistance to targeted medicines. Working with Foundation Medicine to reveal these genomic alterations may help AstraZeneca to research new medicines for people with cancer. Under...Mon, 12 Nov 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=278416&full=1OSAKA, Japan & JUPITER, Fla.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (Takeda) and Envoy Therapeutics Inc. (Envoy) jointly announced today that Takedas wholly-owned subsidiary, Takeda America Holdings, Inc. and Envoy have entered into a definitive agreement for Takeda America Holdings to acquire Envoy. Takeda expects that the transaction will be finalized in the next few days. Under...Tue, 06 Nov 2012 12:00:00 AM GMThttp://www.vcstar.com/news/2012/oct/25/amgen-closes-deal-with-financial-firm-to-open/<a href"http://www.biospace.com/company_profile.aspx?CompanyId1277&typepartner&sourceNewsStoryProfile"><b>Amgen</b></a> | <a href"http://www.biospace.com/jobs/search-results/CustomerId247739?typepartner&sourceNewsStoryJobs"><b>Jobs at Amgen</b></a><br><br>Amgen and Kleiner Perkins Caufield & Byers (KPCB) have founded a new drug development firm, Atara Biotherapeutics, focused on chronic...Mon, 29 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=276734&full=1<a href"http://www.biospace.com/company_profile.aspx?CompanyId1476&typepartner&sourceNewsStoryProfile"><b>Pfizer Inc.</b></a> | <a href"http://www.biospace.com/jobs/search-results/CustomerId394762?typepartner&sourceNewsStoryJobs"><b>Jobs at Pfizer Inc.</b></a><br><br>NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its intention to acquire NextWave Pharmaceuticals, a...Tue, 23 Oct 2012 12:00:00 AM GMTMerck (NYSE: MRK), known as MSD outside the United States and Canada, and AiCuris today announced that they have entered into an exclusive worldwide licensing agreement for AiCuris' novel portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of HCMV infection...Tue, 16 Oct 2012 12:00:00 AM GMThttp://www.nasdaq.com/article/theravance-reaches-collaboration-deal-with-merck-for-up-to-153-million-20121016-00701#.UH11KGcw86hTheravance Inc. (THRX) signed a collaboration agreement with Merck & Co. (MRK) to develop and commercialize the biopharmaceutical company's product candidates for hypertension and heart failure in a deal valued at up to $153 million. Merck would receive exclusive global license to Theravance's drug candidates. Theravance will receive $5 million upfront and up to $148 million in milestone payments...Tue, 16 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=275322&full=1LONDON, UK I October 8, 2012 I AstraZeneca and Ardelyx today announced a worldwide exclusive licensing agreement for Ardelyxs NHE3 inhibitor programme, including the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). NHE3 is the sodiumhydrogen antiporter 3, a protein essential in the absorption of...Tue, 09 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=274564&full=1HAMBURG, Germany, Oct 1, 2012 (Menafn - GlobeNewswire via COMTEX) --Evotec AG (frankfurt:EVT) (TecDAX) today announced that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Both parties will contribute innovative drug targets and high quality technology infrastructures and will...Mon, 01 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=273563&full=1ROCKVILLE, Md.</span> and SURESNES, <span class"xn-location">France</span>, <span class"xn-chron">Sept. 20, 2012</span> /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, <span class"xn-location">France</span>'s largest privately-held pharmaceutical company, announced today that they have entered into an option...Thu, 20 Sep 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=273407&full=1DEERFIELD, Ill. & NEWTOWN, Pa.--(BUSINESS WIRE)-- Baxter International Inc. (BAX) and Onconova Therapeutics, Inc. today announced that they have entered into a European licensing agreement for rigosertib, a novel targeted anti-cancer compound currently in a Phase III study for the treatment of a group of rare hematologic malignancies called Myelodysplastic Syndromes (MDS) and in a Phase II/III study...Wed, 19 Sep 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120917MOUNTAIN VIEW, Calif. and SHENZHEN, China, Sept. 17, 2012 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (GNOM) ("Complete"), an innovative leader in whole human genomic sequencing, and BGI-Shenzhen ("BGI"), a leading international genomics company based in Shenzhen, China, today announced that they have entered into a definitive merger agreement. Through this agreement, a wholly-owned U.S. subsidiary...Mon, 17 Sep 2012 12:00:00 AM GMThttp://www.pmlive.com/pharma_news/astrazeneca_forges_cro_alliance_to_bring_biologic_to_china_424425 <div class"xn-content"><p><span class"xn-location">GAITHERSBURG, Md.</span> and <span class"xn-location">SHANGHAI</span>, <span class"xn-chron">Sept. 10, 2012</span> /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, a leading research and development outsourcing company, today announced that they have formed a joint venture to develop and commercialize MEDI...Tue, 11 Sep 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/08/30/us-genmab-johnson-idUSBRE87T08420120830Genmab A/S (GEN), a Danish biotechnology company, rose the most in more than a year after it said Johnson & Johnson (JNJ) licensed its experimental treatment for multiple myeloma. Genmab shares rose as much as 25 percent, the biggest intraday gain since Aug. 9, 2011, and were up 20 percent to 81 kroner as of 10:25 a.m. in Copenhagen. The agreement with J&Js Janssen unit for daratumumab may be worth...Fri, 31 Aug 2012 12:00:00 AM GMThttp://www.pharmpro.com/news/2012/08/business-Allergan-and-Molecular-partners-enter-into-exclusive-alliance/Irvine, California, USA / Zurich-Schlieren, Switzerland, August 21, 2012. Allergan, Inc. (NYSE: AGN) and Molecular Partners AG today announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.</p><p>Molecular...Tue, 21 Aug 2012 12:00:00 AM GMThttp://www.pharmpro.com/news/2012/08/business-Regulus-Therapeutics-Forms-Strategic-Alliance/Regulus Therapeutics has formed a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for cardiovascular and metabolic diseases and oncology. The collaboration will focus on three microRNA targets, which include Regulus' lead cardiovascular/metabolic disease program targeting microRNA-33 for the treatment of atherosclerosis. According to the agreement...Wed, 15 Aug 2012 12:00:00 AM GMThttp://www.thepharmaletter.com/file/115660/elan-to-spin-off-discovery-science-and-neotope-biosciences.htmlIreland's Elan (ELN.I) said on Monday it would spin off its Neotope drug discovery business platform as a separate public company in a move making Elan immediately profitable. The decision to split the company comes hard on the heels of the failure of an experimental Alzheimer's drug being developed with Pfizer (PFE.N) and Johnson & Johnson (JNJ.N), although Chief Executive Kelly Martin said it had...Tue, 14 Aug 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120810by Richard Daverman, PhD</p><p>August 10, 2012 -- S*BIO of Singapore has sold worldwide rights for a clinical stage oncology drug to MEI Pharma of San Diego. Pracinostat is an oral histone deacetylase (HDAC) inhibitor. The drug has completed Phase II clinical trials in patients with hematologic disorders such as acute myeloid leukemia and myelofibrosis. To make the acquisition, MEI Pharma will...Fri, 10 Aug 2012 12:00:00 AM GMThttp://www.washingtonpost.com/world/europe/glaxosmithkline-completes-36-billion-takeover-of-human-genome-sciences/2012/08/03/9a0fe0fc-dd7b-11e1-8ad1-909913931f71_story.htmlWashington Business Journal by Jeff Clabaugh, Broadcast/Web Reporter </p><p>GlaxoSmithKline PLC has completed its $3.6 billion takeover of Rockville-based Human Genome Sciences Inc., the final step in a months-long struggle for control of the company.</p><p>All outstanding shares of Human Genome were acquired for $14.25 per share in cash.</p><p>Human Genome Sciences agreed last month to...Mon, 06 Aug 2012 12:00:00 AM GMThttp://www.xconomy.com/san-diego/2012/07/16/life-technologies-buys-navigenics-in-new-gene-diagnostics-strategy/ CARLSBAD, Calif.</span>, <span class"xn-chron">July 16, 2012</span> /PRNewswire/ -- <a href"http://www.lifetech.com/" target"_blank">Life Technologies Corporation</a> (NASDAQ: LIFE) today announced the acquisition of Navigenics, Inc. This acquisition represents Life Technologies' first step in executing against a strategy to build out its molecular diagnostics business through internal development...Tue, 17 Jul 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/07/16/us-gsk-human-genome-idUSBRE86F00L20120716GlaxoSmithKline is expected to announce a deal to buy Human Genome Sciences for about $2.8 billion as soon as Monday, ending a three-month hostile pursuit of the U.S. biotech company on friendly terms after sweetening its offer. Sources familiar with the situation said Britain's biggest drugmaker was set to pay around $14 per share, up from $13 offered previously, which Human Genome - an early pioneer...Mon, 16 Jul 2012 12:00:00 AM GMThttp://www.masshightech.com/stories/2012/07/09/daily39-Verastem-buys-Pfizer-cancer-drug-candidate.htmlEisai and Versatem inked a research collaboration focused on the development of small molecule Wnt inhibitors. Verastem separately reported acquiring exclusive global rights to Pfizers Phase II-ready focal adhesion kinase (FAK) inhibitor PF-04554878. The drug, designated VS-6063 by Verastem, is being developed for the treatment of solid tumors and is projected to start in Phase II development for...Thu, 12 Jul 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120712CAMBRIDGE, Mass. & HANGZHOU, China & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (ALNY), a leading RNAi therapeutics company, and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd.., a privately held US-China joint venture pharmaceutical company, announced today that they have formed a strategic collaboration for the development of ALN-VSP, a first-in-class, systemically...Thu, 12 Jul 2012 12:00:00 AM GMThttp://www.washingtonpost.com/business/industries/bristol-myers-agrees-to-acquire-amylin-pharmaceuticals-for-5-billion-in-cash/2012/07/01/gJQAF6L8FW_story.htmlBristol-Myers Squibb Co. (NASDAQ:BMY) and AstraZeneca plc (NYSE:AZN) have teamed up to execute a uniquely structured takeover of diabetes firm Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) for a total value of $7 billion - the fourth and largest billion-dollar-plus deal of 2012.<br><br>Amylin's assets include GLP-1 agonists Byetta (exenatide) and its extended release equivalent Bydureon, Metreleptin...Tue, 03 Jul 2012 12:00:00 AM GMThttp://www.genengnews.com/gen-news-highlights/genentech-taps-ac-immune-in-second-alzheimer-drug-development-deal/81246915/Roche Holding AG (ROG) bought the rights to an experimental drug for Alzheimers disease from closely held AC Immune, its second deal with the Swiss company. Roches Genentech unit will pay an undisclosed amount for rights to AC Immunes anti-Tau antibodies, plus more than 400 million Swiss francs ($421 million) if the drugs meet targets, Lausanne-based AC Immune said in a statement today. Roche will...Tue, 19 Jun 2012 12:00:00 AM GMThttp://www.nasdaq.com/article/astrazeneca-rigel-to-develop-asthma-treatment-20120619-00755MOLNDAL, Sweden and <span class"xn-location">SOUTH SAN FRANCISCO, Calif.</span>, <span class"xn-chron">June 19, 2012</span> /PRNewswire/ -- AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated...Tue, 19 Jun 2012 12:00:00 AM GMThttp://www.telegraph.co.uk/finance/markets/marketreport/9325348/GSK-rumoured-to-be-buying-5bn-BioMarin.htmlThe pharmaceutical giant's hostile $2.6bn (1.7bn) takeover bid for US-based Human Genome Sciences has provided those traders and hedge funds that bet on takeover deals a rare moment of excitement in a lacklustre dealmaking environment. However, yesterday Glaxo was linked with a new multi-billion dollar takeover bid for a US pharmaceutical company. Last week reports suggested Shire, up 12p at 18...Wed, 13 Jun 2012 12:00:00 AM GMThttp://www.pharmatimes.com/Article/12-06-12/GSK_unit_pays_%C2%A3146_million_to_get_Basilea_eczema_drug.aspx<div id"releaseBody"><p>BASEL, SWITZERLAND--(Marketwire - June 11, 2012) - Basilea Pharmaceutica AG /Basilea enters into global agreement with Stiefel, a GSK company, forToctino&#174;(alitretinoin). Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.<p><pre> * Stiefel gains exclusive worldwide rights to Toctino...Tue, 12 Jun 2012 12:00:00 AM GMThttp://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/9309426/AstraZeneca-4bn-approach-for-diabetes-specialist-Amylin.htmlThe British pharmaceutical giant is among several potential suitors for the company. Amylin has already rejected a $3.5bn approach from Bristol Myers Squibb, a fellow US drugs company that is thought to have made a renewed offer. Other names that have been linked to a possible deal include US drug maker Merck, and Sanofi, the French pharmaceuticals group that employs 1,800 people in Britain. For Astra...Tue, 05 Jun 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=261638&full=1<div id"releaseBody"><p>BASEL, SWITZERLAND--(Marketwire - May 25, 2012) - <p><br>Basilea Pharmaceutica AG /Basilea participates in public-private collaboration to tackle antibioticresistance. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.<p>Basilea Pharmaceutica Ltd. welcomes thelaunch in Europe of a...Fri, 25 May 2012 12:00:00 AM GMThttp://www.boston.com/business/articles/2012/05/17/agilent_and_swedish_investors_ink_deal_to_buy_dako/SANTA CLARA, Calif. & GLOSTRUP, Denmark--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE:A) and EQT, the Sweden-based private equity group, today announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilents history. </p><p>In the rapidly growing diagnostics...Thu, 17 May 2012 12:00:00 AM GMThttp://www.washingtonpost.com/blogs/capital-business/post/glaxosmithkline-appeals-directly-to-human-genome-sciences-shareholders-in-buyout-dispute/2012/05/09/gIQANa7nCU_blog.htmlGlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board. The decision to go hostile with the $13 a share cash tender offer sets GSK up for a potentially lengthy battle with those Human Genome investors who believe it is not offering enough. "They will do fantastically...Thu, 10 May 2012 12:00:00 AM GMThttp://www.washingtonpost.com/business/industries/novartiss-sandoz-unit-will-buy-ny-based-fougera-become-biggest-generic-dermatology-company/2012/05/02/gIQAisVMxT_story.htmlNovartis AG (NOVN), Europes largest drugmaker, said it will spend $1.5 billion for closely held Fougera Pharmaceuticals Inc. in a deal to become the top seller of generic skin medications. Fougera, based in Melville, New York, had sales of about $429 million in 2011 and is owned by private equity funds, including Nordic Capital, Avista Capital Partners and DLJ Merchant Banking, a subsidiary of Credit...Thu, 03 May 2012 12:00:00 AM GMThttp://www.pipelinereview.com/index.php/2012050147788/RD-Licensing/Axerion-Therapeutics-and-AstraZeneca-to-Develop-and-Commercialize-a-Biologic-Approach-for-the-Treatment-of-Alzheimers-Disease.htmlNEW HAVEN, CT, USA I May 1, 2012 I Axerion Therapeutics, Inc., a private Connecticut-based biotechnology company, and MedImmune the global biologics arm of AstraZeneca, announced today that they have entered into a research collaboration and sublicense arrangement to develop and commercialize a biologic approach for the treatment of Alzheimer's disease.</p><p>The agreement with Axerion is the first...Wed, 02 May 2012 12:00:00 AM GMThttp://www.rttnews.com/1865066/reports-amylin-seeks-buyers.aspx?type=bn&utm_source=google&utm_campaign=sitemapAmylin Pharmaceuticals Inc (NSQ:AMLN - News), which spurned a $3.5 billion takeover bid from Bristol-Myers Squibb Co (NYS:BMY - News) and is fending off a lawsuit from activist investor Carl Icahn, started reaching out to potential buyers last week, sources familiar with the situation said on Sunday. Amylin, maker of diabetes drugs Byetta and Bydureon, has hired Credit Suisse (VTX:CSGN.VX - News) and...Tue, 24 Apr 2012 12:00:00 AM GMThttp://www.washingtonpost.com/business/industries/astrazeneca-buying-us-biotech-firm-ardea-in-deal-worth-126-bln/2012/04/23/gIQA7MfibT_story.html<div id"releaseBody"><p>SAN DIEGO,CA--(Marketwire - April 23, 2012) - AstraZeneca and Ardea Biosciences, Inc. (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerRDEA">RDEA</a>) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development...Mon, 23 Apr 2012 12:00:00 AM GMThttp://www.washingtonpost.com/blogs/capital-business/post/human-genome-services-receives-buyout-offer-from-glaxosmithkline/2012/04/19/gIQAwThsST_blog.html(Reuters) - Human Genome Sciences Inc said it had rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector that has been swept by M&A recently.Fri, 20 Apr 2012 12:00:00 AM GMThttp://www.washingtonpost.com/business/roche-to-end-bid-to-buy-us-diagnostics-firm-illumina-in-deal-valued-at-about-65-billion/2012/04/18/gIQApsEdQT_story.html(Reuters) - Roche might be better off dropping its $6.80 billion bid for genomics specialist Illumina and coming back a year later, as its legacy of paying up after protracted takeovers has damaged its bargaining power, some bankers believe.Thu, 19 Apr 2012 12:00:00 AM GMThttp://www.nasdaq.com/article/amgen-to-acquire-privately-held-kai-pharmaceuticals-for-315-mln-in-cash-20120410-00650THOUSAND OAKS, Calif.</span> and <span class"xn-location">SOUTH SAN FRANCISCO, Calif.</span>, <span class"xn-chron">April 10, 2012</span> /PRNewswire/ -- Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco. KAI's lead product candidate, KAI-4169, is a novel agent being initially...Wed, 11 Apr 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/03/21/us-actavis-watson-idUSBRE82K0ZK20120321Watson Pharmaceuticals Inc (WPI.N) is close to buying Swiss-based Actavis for around $7 billion, marking the latest deal between generics companies racing to achieve economies of scale, three sources familiar with the matter said. The deal would involve U.S.-based Watson, already among the world's five largest generic drugmakers, paying between 5.0 billion and 5.5 billion euros ($6.6-7.3 billion) for...Thu, 22 Mar 2012 12:00:00 AM GMThttp://www.news-medical.net/news/20120320/Heptares-exercises-exclusive-option-to-license-new-A2A-antagonist-for-CNS-disorders.aspxWELWYN GARDEN CITY, England and BOSTON, Massachusetts, March 20, 2012 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical...Tue, 20 Mar 2012 12:00:00 AM GMThttp://www.sun-sentinel.com/health/sns-rt-us-india-bioconbre82c08z-20120312,0,1760238.storyBANGALORE, India & NEW YORK--(BUSINESS WIRE)--Biocon and Pfizer today announced the conclusion of their alliance to commercialize Biocons biosimilar versions of Insulin and Insulin analog products. The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently.</p><p>Biocon and Pfizer are committed...Wed, 14 Mar 2012 12:00:00 AM GMThttp://www.genengnews.com/gen-news-highlights/gsk-taps-epistem-for-amplification-platform-to-identify-fibrosis-biomarkers/81246485/MANCHESTER, UNITED KINGDOM--(Marketwire -03/13/12)- Epistem Plc (LSE: EHP.L - News) ("Epistem" or "the Company"), the UK biotechnology and personalised medicine company, is pleased to announce a three year biomarker collaboration with GlaxoSmithKline in the field of fibrosis research. The collaboration will focus on identifying key characteristics of diseased fibrotic tissue on which Epistem will apply...Tue, 13 Mar 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=252251&full=1CAMBRIDGE, MASS. MARCH 7, 2012 Mersana Therapeutics, Inc. announced today that it has entered into a collaboration agreement with Endo Pharmaceuticals (Nasdaq: ENDP) to develop next-generation antibody-drug conjugates (ADCs). Mersanas proprietary conjugation technology is comprised of the Companys Fleximer polymer and a broad array of customizable linker chemistries for attaching diverse, potent...Wed, 07 Mar 2012 12:00:00 AM GMThttp://www.news-medical.net/news/20120227/GSK-Angiochem-to-develop-and-commercialize-LSD-treatments.aspxMONTREAL--(BUSINESS WIRE)--Angiochem announced today a global collaboration with GlaxoSmithKline (GSK) to discover, develop and commercialize treatments for lysosomal storage diseases (LSDs). The collaboration will combine Angiochems expertise in creating novel therapeutics that cross the blood-brain barrier (BBB) with the scientific, development and commercialization capability of GSK in rare diseases...Mon, 27 Feb 2012 12:00:00 AM GMThttp://www.masshightech.com/stories/2012/02/20/daily1-Enantas-Hep-C-drug-deal-with-Novartis-worth-up-to-440M.htmlWATERTOWN, Mass.</span>, <span class"xn-chron">Feb. 21, 2012</span> /PRNewswire/ -- <a href"http://www.enanta.com/" target"_blank">Enanta Pharmaceuticals, Inc.</a>, a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that it has entered into an exclusive collaboration and license agreement with Novartis for...Wed, 22 Feb 2012 12:00:00 AM GMThttp://www.inpharm.com/news/171418/pfizer-closes-545m-china-generics-dealFebruary 20, 2012 -- Pfizer and Zhejiang Hisun Pharma will put $545 million of assets into their branded generics JV. The investment will consist of off-patent drugs, manufacturing sites and cash. Hisun will contribute $295 million of these assets for a 51% stake in the JV, while Pfizers portion will be $250 million for the remaining 49%. The two companies signed a MOU to set up the JV in June 2...Tue, 21 Feb 2012 12:00:00 AM GMThttp://www.reuters.com/article/2012/02/08/us-roche-illumina-idUSTRE8170PT20120208BASEL, Switzerland--(BUSINESS WIRE)--Roche (SIX: RO, ROG; OTCQX: RHHBY) released the following statement in response to the announcement by Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has recommended that shareholders not tender their shares to Roche. On January 27, 2012, Roche commenced a tender offer to purchase all outstanding shares of Illumina for $44.50 per share in cash, or an...Fri, 10 Feb 2012 12:00:00 AM GMThttp://www.pharmatimes.com/Article/12-02-03/Merck_KGaA_signs_550_million_cancer_pact_with_Threshold.aspxDARMSTADT, Germany, Feb 03, 2012 (BUSINESS WIRE) -- --Deal provides Threshold with an upfront payment of EUR 19 million ($25 million), plus further potential milestones and royalties as well as an option to co-commercialize in the United States </p><p>Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc...Fri, 03 Feb 2012 12:00:00 AM GMThttp://www.xconomy.com/boston/2012/01/17/genentech-pours-95m-into-constellations-epigenetic-drug-platform/CAMBRIDGE, Mass., Jan 17, 2012 (BUSINESS WIRE) -- Constellation Pharmaceuticals, Inc., today announced that it has entered into a major strategic agreement with Genentech, a member of the Roche Group (six:RO)(six:ROG)(otcqx:RHHBY), to launch a broad collaboration based on the science of epigenetics and chromatin biology to discover and develop innovative treatments for cancer and other serious diseases...Tue, 17 Jan 2012 12:00:00 AM GMThttp://www.thepharmaletter.com/file/110139/xenon-in-646-million-deal-with-roche-unit.html<div class"xn-content"><p><span class"xn-location">VANCOUVER, British Columbia</span>, <span class"xn-chron">Jan. 9, 2012</span> /PRNewswire/ -- Xenon today announced a strategic alliance with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to discover and develop compounds and companion diagnostics for the potential treatment of pain.</p><p>"We are delighted to be collaborating...Tue, 10 Jan 2012 12:00:00 AM GMThttp://www.washingtonpost.com/business/bristol-myers-ups-its-hepatitis-c-game-fast-with-a-25-billion-acquisition-of-inhibitex/2012/01/08/gIQAh1pAkP_story.htmlNEW YORK & PRINCETON, N.J. & ATLANTA--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY - News) and Inhibitex, Inc. (Nasdaq:INHX - News) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price...Mon, 09 Jan 2012 12:00:00 AM GMThttp://www.xconomy.com/boston/2012/01/05/forma-cuts-65m-deal-with-boehringer-ingelheim-to-discover-cancer-drugs/WATERTOWN, Mass.--(BUSINESS WIRE)-- FORMA Therapeutics announced today that the Company has entered into a research and development collaboration with Boehringer Ingelheim to discover and develop novel drug candidates for the treatment of cancer. The agreement will focus on discovering small molecule drugs against oncology-relevant protein-protein interactions. </p><p>Under the terms of the collaboration...Thu, 05 Jan 2012 12:00:00 AM GMThttp://www.masshightech.com/stories/2011/12/26/daily15-Alexion-to-pay-up-to-1B-for-Enobia.htmlCHESHIRE, Conn. & MONTREAL, CANADA--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and Enobia Pharma Corp. today announced that the companies have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia. Enobia is a private biopharmaceutical company based in Montreal, Canada and Cambridge, Massachusetts, which is focused on the development of...Thu, 29 Dec 2011 12:00:00 AM GMT